Literature DB >> 9259654

Early BCG vaccination and development of atopy.

J S Alm1, G Lilja, G Pershagen, A Scheynius.   

Abstract

BACKGROUND: The increase in atopic diseases may be partly explicable by a decline of certain infectious diseases, or changes in childhood vaccination programmes, or both. We investigated whether BCG vaccination against tuberculosis influences the development of atopy.
METHODS: We did a retrospective cohort study of 216 children with atopic heredity, born in Stockholm between 1989 and 1992, who received BCG vaccination when they were younger than 6 months, and 358 age-matched controls who had not been vaccinated. Both groups attended Sachs' Children's Hospital, Stockholm, Sweden, during 1995-96 for assessment of atopic history and clinical signs of atopic disease. All children also underwent skin-prick testing (SPT) and serum was analysed for allergen-specific IgE antibodies. Serum from parents was also analysed for IgE antibodies.
FINDINGS: 77 (36%) children in the BCG group and 145 (41%) in the control group had a positive history or clinical signs of atopic disease. In the vaccinated group, 26 (12%) children had one or more positive SPT, and 61 (31%) had circulating allergen-specific IgE antibodies, whereas in the control group, the numbers were 35 (10%) and 84 (27%) respectively. Atopy was confirmed by serology in parents of almost two-thirds of the children in each group. Other risk factors for atopic disease were evenly distributed between the two groups.
INTERPRETATION: Early BCG vaccination in children with atopic heredity does not seem to affect the development of atopic disease before school age.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9259654     DOI: 10.1016/S0140-6736(97)02207-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  34 in total

Review 1.  Worldwide variations in the prevalence of atopic symptoms: what does it all mean?

Authors:  J O Warner
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  Family size, infection and atopy: the first decade of the "hygiene hypothesis".

Authors:  D P Strachan
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 3.  Epidemiology of allergic rhinitis.

Authors:  R Michael Sly
Journal:  Clin Rev Allergy Immunol       Date:  2002-02       Impact factor: 8.667

Review 4.  Pollution and the immune response: atopic diseases--are we too dirty or too clean?

Authors:  D Diaz-Sanchez
Journal:  Immunology       Date:  2000-09       Impact factor: 7.397

5.  Infections, medication use, and the prevalence of symptoms of asthma, rhinitis, and eczema in childhood.

Authors:  Catherine Cohet; Soo Cheng; Claire MacDonald; Michael Baker; Sunia Foliaki; Nyk Huntington; Jeroen Douwes; Neil Pearce
Journal:  J Epidemiol Community Health       Date:  2004-10       Impact factor: 3.710

6.  Immunization and symptoms of atopic disease in children: results from the International Study of Asthma and Allergies in Childhood.

Authors:  H R Anderson; J D Poloniecki; D P Strachan; R Beasley; B Björkstén; M I Asher
Journal:  Am J Public Health       Date:  2001-07       Impact factor: 9.308

7.  Timing of routine immunisations and subsequent hay fever risk.

Authors:  S A Bremner; I M Carey; S DeWilde; N Richards; W C Maier; S R Hilton; D P Strachan; D G Cook
Journal:  Arch Dis Child       Date:  2005-06       Impact factor: 3.791

Review 8.  Translational mini-review series on Toll-like receptors: Toll-like receptor ligands as novel pharmaceuticals for allergic disorders.

Authors:  M Goldman
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

9.  BCG infection in allergen-presensitized rats suppresses Th2 immune response and prevents the development of allergic asthmatic reaction.

Authors:  Y I Koh; I S Choi; W Y Kim
Journal:  J Clin Immunol       Date:  2001-01       Impact factor: 8.317

10.  Analysis of recombinant mycobacteria as T helper type 1 vaccines in an allergy challenge model.

Authors:  R Janssen; A Kruisselbrink; L Hoogteijling; J R Lamb; D B Young; J E Thole
Journal:  Immunology       Date:  2001-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.